Tasly Pharmaceuticals, Inc. clinical trials
Acquired by China Resources Pharmaceutical Group Limited, Mar 27, 2025 · source ↗
The registry lists 17 studies whose lead sponsor is Tasly Pharmaceuticals, Inc.. 1 are recruiting or about to start. Per ClinicalTrials.gov, last updated Apr 9, 2025.
Before and after it joined China Resources Pharmaceutical Group Limited
- First submitted before Tasly Pharmaceuticals, Inc. became part of China Resources Pharmaceutical Group Limited
- 17
- First submitted after Tasly Pharmaceuticals, Inc. became part of China Resources Pharmaceutical Group Limited
- 0
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
Registry sponsor names on this page
- Tasly Pharmaceuticals, Inc.17 studies
Something wrong with this grouping? Tell us on the China Resources Pharmaceutical Group Limited page.
Studies
Recruiting first, then most recently updated. Showing 17 of 17. All China Resources Pharmaceutical Group Limited studies →
- Outcome Research to Confirm the Anti-anginal Effect of T89 in Patients With Stable AnginaRecruitingNCT03789552Phase 3
Sponsor listed in the registry: Tasly Pharmaceuticals, Inc. · First submitted before Tasly Pharmaceuticals, Inc. became part of China Resources Pharmaceutical Group Limited
- Safety and Efficacy of T89 in the Prevention and Treatment of Adults With Acute Mountain Sickness (AMS)CompletedNCT04993729Phase 3
Sponsor listed in the registry: Tasly Pharmaceuticals, Inc. · First submitted before Tasly Pharmaceuticals, Inc. became part of China Resources Pharmaceutical Group Limited
- Expanded Access to T89 for Treatment Use in Intermediate-size Patients Population With COVID-19No longer availableNCT04646031
Sponsor listed in the registry: Tasly Pharmaceuticals, Inc. · First submitted before Tasly Pharmaceuticals, Inc. became part of China Resources Pharmaceutical Group Limited
- A Clinical Study to Evaluate the Safety and Efficacy of T92 in Pediatric Patients With Tourette SyndromeStatus unknownNCT05188274Not applicable
Sponsor listed in the registry: Tasly Pharmaceuticals, Inc. · First submitted before Tasly Pharmaceuticals, Inc. became part of China Resources Pharmaceutical Group Limited
- Evaluate the Efficacy, Safety and Tolerability of TSUPPORT for Adults With Tourette SyndromeStatus unknownNCT05183594Not applicable
Sponsor listed in the registry: Tasly Pharmaceuticals, Inc. · First submitted before Tasly Pharmaceuticals, Inc. became part of China Resources Pharmaceutical Group Limited
- The Effect of T89 on Improving Oxygen Saturation and Clinical Symptoms in Patients With COVID-19WithdrawnNCT04285190Not applicable
Sponsor listed in the registry: Tasly Pharmaceuticals, Inc. · First submitted before Tasly Pharmaceuticals, Inc. became part of China Resources Pharmaceutical Group Limited
- Safety and Efficacy of T89 in Prevention and Treatment of Adults With Acute Mountain Sickness (AMS)CompletedNCT03552263Phase 2
Sponsor listed in the registry: Tasly Pharmaceuticals, Inc. · First submitted before Tasly Pharmaceuticals, Inc. became part of China Resources Pharmaceutical Group Limited
- Effects of Deepure(Pu-erh Tea Extract) on Glycemic ControlStatus unknownNCT03613688Not applicable
Sponsor listed in the registry: Tasly Pharmaceuticals, Inc. · First submitted before Tasly Pharmaceuticals, Inc. became part of China Resources Pharmaceutical Group Limited
- Study of Compound Danshen Dripping Pills to Treat Acute Mountain SicknessCompletedNCT03270787Phase 1/2
Sponsor listed in the registry: Tasly Pharmaceuticals, Inc. · First submitted before Tasly Pharmaceuticals, Inc. became part of China Resources Pharmaceutical Group Limited
- Phase III Study of Compound Danshen Dripping Pills to Treat Diabetic RetinopathyStatus unknownNCT02388984Phase 3
Sponsor listed in the registry: Tasly Pharmaceuticals, Inc. · First submitted before Tasly Pharmaceuticals, Inc. became part of China Resources Pharmaceutical Group Limited
- A Study of Ginsenoside H Dripping Pills for Advanced Non-Small Cell Lung Cancer (NSCLC)Status unknownNCT02714608Phase 2
Sponsor listed in the registry: Tasly Pharmaceuticals, Inc. · First submitted before Tasly Pharmaceuticals, Inc. became part of China Resources Pharmaceutical Group Limited
- Phase III Trial of Dantonic® (T89) Capsule to Prevent and Treat Stable AnginaCompletedNCT01659580Phase 3
Sponsor listed in the registry: Tasly Pharmaceuticals, Inc. · First submitted before Tasly Pharmaceuticals, Inc. became part of China Resources Pharmaceutical Group Limited
- Dose-Escalate Study to Investigate the Safety and Tolerability of T89 in JapaneseCompletedNCT01679028Phase 1
Sponsor listed in the registry: Tasly Pharmaceuticals, Inc. · First submitted before Tasly Pharmaceuticals, Inc. became part of China Resources Pharmaceutical Group Limited
- Phase III Study of 5LGr to Treat Tic DisorderCompletedNCT01501695Phase 3
Sponsor listed in the registry: Tasly Pharmaceuticals, Inc. · First submitted before Tasly Pharmaceuticals, Inc. became part of China Resources Pharmaceutical Group Limited
- Phase II Multi-Center Study of T89 to Treat Chronic Stable AnginaCompletedNCT00797953Phase 2
Sponsor listed in the registry: Tasly Pharmaceuticals, Inc. · First submitted before Tasly Pharmaceuticals, Inc. became part of China Resources Pharmaceutical Group Limited
- A Study to Evaluate the Effect of T89(Dantonic®)on Steady-State Pharmacodynamics of WarfarinCompletedNCT01475279Phase 1
Sponsor listed in the registry: Tasly Pharmaceuticals, Inc. · First submitted before Tasly Pharmaceuticals, Inc. became part of China Resources Pharmaceutical Group Limited
- A Study To Evaluate The Effect of T89(Dantonic®)On P450 EnzymesCompletedNCT01473888Phase 1
Sponsor listed in the registry: Tasly Pharmaceuticals, Inc. · First submitted before Tasly Pharmaceuticals, Inc. became part of China Resources Pharmaceutical Group Limited